Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Jan 2000

Kandioler-Eckersberger D, Ludwig C, Rudas M, Kappel S, Janschek E, Wenzel C, Schlagbauer-Wadl H, Mittlböck M, Gnant M, Steger G, Jakesz R

Abstract excerpt

The value of p53 to predict the cytotoxic effect of two commonly used chemotherapy regimens was assessed in patients with advanced breast cancer. Response to a DNA-damaging combination therapy [fluorouracil, epirubicin, cyclophosphamide (FEC] considered to induce p53-dependent apoptosis was compared with a microtubule stabilizing therapy (paclitaxel) expected to be independent of p53 function. The p53 status of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Phytogenic
Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cyclophosphamide

Share to Epirubicin

Share to Fluorouracil

Share to Genes, p53

Share to Neoadjuvant Therapy

Share to Paclitaxel

Source

Identifiers

PMID: 10656431

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients.PMID 10656431Read ↗

Gene expression signature of TP53 but not its mutation status predicts response to sequential paclitaxel and 5-FU/epirubicin/cyclophosphamide in human breast cancer.Semantic proximity Read ↗

Predictive and prognostic role of p53 according to tumor phenotype in breast cancer patients treated with preoperative chemotherapy: a single-institution analysis.Semantic proximity Read ↗

TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial.Semantic proximity Read ↗

TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting.Semantic proximity Read ↗

TP53 status and response to chemotherapy in breast cancer.Semantic proximity Read ↗

Cancer therapy and p53Semantic proximity Read ↗

Molecular mechanisms of apoptosis and chemosensitivity to platinum and paclitaxel in ovarian cancer: biological data and clinical implications.Semantic proximity Read ↗

Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy.Semantic proximity Read ↗

p53 mutations in epithelial ovarian cancers: possible role in predicting chemoresistance.Semantic proximity Read ↗

TP53 and MYC gene alterations independently predict poor prognosis in breast cancer patients.Semantic proximity Read ↗

TP53 Mutations and Outcomes in Breast Cancer: Reading beyond the Headlines.Semantic proximity Read ↗

Exploiting p53 status to enhance effectiveness of chemotherapy by lowering associated toxicity.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.